Cognitive impairment and dementia in Parkinson's disease: a controlled study

1991 ◽  
Vol 21 (4) ◽  
pp. 911-921 ◽  
Author(s):  
J. L. Boyd ◽  
C. A. Cruickshank ◽  
C. W. Kenn ◽  
P. Madeley ◽  
R. H. S. Mindham ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Longitudinal Study ◽  
Motor Function ◽  
Depressed Mood ◽  
Motor Impairment ◽  
Controlled Study ◽  
Healthy Control ◽  
Mood Effects

SYNOPSISThe performance of 47 patients with Parkinson's disease on a battery of tests of cognition, motor function, disability and mood was compared with the performance of 47 healthy control subjects who were matched to the patients on the basis of age, sex and pre-morbid IQ. An increased prevalence of impairment over a range of cognitive functions was observed in the Parkinson's disease patients as compared with their matched controls. The differences between the Parkinson's disease patients and controls could not be accounted for by factors such as depressed mood, effects of medication or motor impairment. Our findings are discussed in relation to the methodology of previous studies in this area and to the need for a comprehensive clinico-pathological longitudinal study.

Obstructive sleep apnea, CPAP therapy and Parkinson's disease motor function: A longitudinal study

2020 ◽  
Vol 70 ◽  
pp. 45-50 ◽  
Author(s):  
Lingrui Meng ◽  
Andrea Benedetti ◽  
Anne-Louise Lafontaine ◽  
Victoria Mery ◽  
Ann Ross Robinson ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Obstructive Sleep Apnea ◽  
Longitudinal Study ◽  
Sleep Apnea ◽  
Motor Function ◽  
Cpap Therapy ◽  
Obstructive Sleep

scholarly journals Dynamic functional connectivity changes associated with dementia in Parkinson’s disease

Brain ◽  
2019 ◽  
Vol 142 (9) ◽  
pp. 2860-2872 ◽  
Author(s):  
Eleonora Fiorenzato ◽  
Antonio P Strafella ◽  
Jinhee Kim ◽  
Roberta Schifano ◽  
Luca Weis ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Functional Connectivity ◽  
Parkinson’S Disease Dementia ◽  
Dynamic Functional Connectivity ◽  
Control Subjects ◽  
Healthy Control ◽  
Normal Cognition

AbstractDynamic functional connectivity captures temporal variations of functional connectivity during MRI acquisition and it may be a suitable method to detect cognitive changes in Parkinson’s disease. In this study, we evaluated 118 patients with Parkinson’s disease matched for age, sex and education with 35 healthy control subjects. Patients with Parkinson’s disease were classified with normal cognition (n = 52), mild cognitive impairment (n = 46), and dementia (n = 20) based on an extensive neuropsychological evaluation. Resting state functional MRI and a sliding-window approach were used to study the dynamic functional connectivity. Dynamic analysis suggested two distinct connectivity ‘States’ across the entire group: a more frequent, segregated brain state characterized by the predominance of within-network connections, State I, and a less frequent, integrated state with strongly connected functional internetwork components, State II. In Parkinson’s disease, State I occurred 13.89% more often than in healthy control subjects, paralleled by a proportional reduction of State II. Parkinson’s disease subgroups analyses showed the segregated state occurred more frequently in Parkinson’s disease dementia than in mild cognitive impairment and normal cognition groups. Further, patients with Parkinson’s disease dementia dwelled significantly longer in the segregated State I, and showed a significant lower number of transitions to the strongly interconnected State II compared to the other subgroups. Our study indicates that dementia in Parkinson’s disease is characterized by altered temporal properties in dynamic connectivity. In addition, our results show that increased dwell time in the segregated state and reduced number of transitions between states are associated with presence of dementia in Parkinson’s disease. Further studies on dynamic functional connectivity changes could help to better understand the progressive dysfunction of networks between Parkinson’s disease cognitive states.

scholarly journals Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER)

2010 ◽  
Vol 26 (1) ◽  
pp. 90-99 ◽  
Author(s):  
Claudia Trenkwalder ◽  
Bryan Kies ◽  
Monika Rudzinska ◽  
Jennifer Fine ◽  
Janos Nikl ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Function ◽  
Early Morning ◽  
Controlled Study ◽  
Double Blind

scholarly journals The Signaling and Pharmacology of the Dopamine D1 Receptor

2022 ◽  
Vol 15 ◽  
Author(s):  
Jace Jones-Tabah ◽  
Hanan Mohammad ◽  
Emma G. Paulus ◽  
Paul B. S. Clarke ◽  
Terence E. Hébert
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Neuronal Excitability ◽  
Motor Behavior ◽  
Motor Impairment ◽  
Dopamine D1 Receptor ◽  
D1 Receptor ◽  
Target Cells ◽  
The Brain

The dopamine D1 receptor (D1R) is a Gαs/olf-coupled GPCR that is expressed in the midbrain and forebrain, regulating motor behavior, reward, motivational states, and cognitive processes. Although the D1R was initially identified as a promising drug target almost 40 years ago, the development of clinically useful ligands has until recently been hampered by a lack of suitable candidate molecules. The emergence of new non-catechol D1R agonists, biased agonists, and allosteric modulators has renewed clinical interest in drugs targeting this receptor, specifically for the treatment of motor impairment in Parkinson's Disease, and cognitive impairment in neuropsychiatric disorders. To develop better therapeutics, advances in ligand chemistry must be matched by an expanded understanding of D1R signaling across cell populations in the brain, and in disease states. Depending on the brain region, the D1R couples primarily to either Gαs or Gαolf through which it activates a cAMP/PKA-dependent signaling cascade that can regulate neuronal excitability, stimulate gene expression, and facilitate synaptic plasticity. However, like many GPCRs, the D1R can signal through multiple downstream pathways, and specific signaling signatures may differ between cell types or be altered in disease. To guide development of improved D1R ligands, it is important to understand how signaling unfolds in specific target cells, and how this signaling affects circuit function and behavior. In this review, we provide a summary of D1R-directed signaling in various neuronal populations and describe how specific pathways have been linked to physiological and behavioral outcomes. In addition, we address the current state of D1R drug development, including the pharmacology of newly developed non-catecholamine ligands, and discuss the potential utility of D1R-agonists in Parkinson's Disease and cognitive impairment.

Longitudinal study of the levodopa motor response in Parkinson's disease: Relationship between cognitive decline and motor function

2009 ◽  
pp. NA-NA ◽  
Author(s):  
Jane E. Alty ◽  
Benjamin G. Clissold ◽  
Craig D. McColl ◽  
Katrina A. Reardon ◽  
Mark Shiff ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Longitudinal Study ◽  
Cognitive Decline ◽  
Motor Function ◽  
Motor Response

Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study

2020 ◽  
Vol 80 ◽  
pp. 127-132
Author(s):  
Kelly A. Mills ◽  
Ruth B. Schneider ◽  
Marie Saint-Hilaire ◽  
G. Webster Ross ◽  
Robert A. Hauser ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Longitudinal Study ◽  
Cognitive Decline ◽  
Disease Associations

Controlled study of decision-making and cognitive impairment in Parkinson's disease

2007 ◽  
Vol 22 (10) ◽  
pp. 1430-1435 ◽  
Author(s):  
Javier Pagonabarraga ◽  
Carmen García-Sánchez ◽  
Gisela Llebaria ◽  
Berta Pascual-Sedano ◽  
Alexandre Gironell ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Decision Making ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Controlled Study

scholarly journals Clinical Trials in Parkinson's Disease Dementia and Dementia with Lewy Bodies

2007 ◽  
Vol 34 (S1) ◽  
pp. S109-S117 ◽  
Author(s):  
Richard Camicioli ◽  
Serge Gauthier
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Cognitive Impairment ◽  
Dementia With Lewy Bodies ◽  
Motor Impairment ◽  
Lewy Bodies ◽  
Behavioral Impairment ◽  
Consensus Definition ◽  
Therapeutic Implications

Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB) are pathological overlapping and important causes of dementia for which clinical trials are in their infancy. Cholinesterase inhibitors may be of benefit in DLB and PDD, as suggested by placebo-controlled clinical trials of rivastigmine and donepezil. The anti-psychotic agent clozapine has been of benefit in PD and PDD, but other agents, such as quetiapine, require adequate assessment. Barriers to trials include pathological overlap that can lead to inaccuracies in clinical diagnosis, unavailability of a consensus definition for PDD, unanswered questions regarding natural history and the paucity of validated outcome measures. Motor impairment must be considered in patients with PDD and DLB; conversely, cognitive impairment should be assessed in trials targeting motor impairment in advanced PD. Potential targets for treatment include onset of dementia, cognitive impairment, behavioral impairment, functional decline, falls, nursing home placement, mortality, quality of life and economic impact. Biomarkers including neuroimaging and cerebrospinal fluid markers are not currently established. At present PDD and DLB are distinct entities by definition. Future studies, including clinical trials and biomarker studies, will help to further define the clinical and therapeutic implications of this distinction.

Sign in / Sign up

Export Citation Format

Share Document